Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. - Wikidata - thesis-toulmin - TriplyDB

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

http://www.wikidata.org/entity/Q34285599

about

Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs.Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes.Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model Multidrug-resistant tuberculosis in Europe, 2010-2011 Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010.Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.The need to accelerate access to new drugs for multidrug-resistant tuberculosis.Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance.Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.High Rates of Treatment Success in Pulmonary Multidrug-Resistant Tuberculosis by Individually Tailored Treatment Regimens.Transmission is a Noticeable Cause of Resistance Among Treated Tuberculosis Patients in Shanghai, China.Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis.Drug-Resistant Tuberculosis among Children, China, 2006-2015.Reply to Soman et al, Alffenaar et al, Metcalfe et al, and Raoult.Analysis of Green Light Committee implementation and acquisition of second-line drug resistance.Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.Target regimen profiles for treatment of tuberculosis: a WHO document.The Evolution of Strain Typing in the Mycobacterium tuberculosis Complex.To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015.

P2860

Q26765394-705A7B03-6E6B-4150-84BB-AE1A72C7B73E Q26782448-623D76E5-46EF-4407-A1DD-C571FA935565 Q28074085-E75D2A64-5C51-43AC-AD6F-CC82BD321F55 Q28545109-9114F695-74AA-4500-95C9-A06F131D30B1 Q28552001-74DC45F8-31F6-401B-99BE-44A4AF328E93 Q28554607-FFF7B30F-9A63-4615-8B22-3CC5FEAF9127 Q29247878-547784F3-FE14-4C66-94B3-56A34C055436 Q30275673-EA8341DD-DC8B-4AF3-9469-D1FF1B198785 Q30278816-1A282E68-253F-419C-8755-E0B6B9D145EF Q30300560-DA9688E8-AD71-4E86-BE85-AB7574371721 Q30379233-7D1625D5-3CB6-48D8-BE46-B64B5DE7C718 Q35130346-3E8E3785-9FB6-437A-8B30-CF425E38D012 Q35673445-857BAE2F-D6FB-4FA7-8108-27C3B9097323 Q35673493-D7CB6305-DC1F-48CB-9B34-E9FA34D7C812 Q35746184-09B7A87F-CD2F-4CC7-9571-9A7B29A8ABAD Q35815071-031CA882-12BE-4AFC-A60B-21DB46780A23 Q35960935-5DE81850-4493-4E85-8A6D-C9B3EFDA8E9D Q36497854-7B2B73FB-00D9-40D3-9B07-4F0E76062483 Q36844683-DCCBEA64-4E09-46B9-A856-A7606EC8DC37 Q36893640-DE463771-5F41-4ADF-A3B5-233456A3A03B Q37675764-26FE1B89-6630-41A8-9CB0-AEA3499412FD Q37677739-3046A0AE-97C2-4191-B057-36D8525C3873 Q38261230-C9ED257B-1DD5-4964-AB8E-41CED51B05F1 Q38644773-03FE26EC-C85B-44ED-B162-34D3EF679BA1 Q38684466-E736FA38-33AE-4336-B721-4C54B03029D3 Q38724073-B41B7498-4F8A-404A-AA3B-CCBE2C80D5B1 Q38763608-57014519-7085-4760-B256-CA635E4A6204 Q38845761-4119C4C1-09CB-495D-9F4A-2D879B20E824 Q39779537-E9D5B5D6-A668-442F-9352-51432F218016 Q40088506-0FCEF9D7-81E1-463A-B486-91419AEB9770 Q40211670-D918B0D1-8B95-4C88-AF24-4FAB122DADA7 Q41009954-7CEBF667-1DD1-4F06-A708-BC55D2FE85D8 Q42650309-E3D74102-B90F-4048-A0F8-E5B2083D27A1 Q43110435-49853F6D-15DE-42E4-9264-8B7A00B3A558 Q46046221-5EBAF010-09B6-437D-B02A-180C7B64A2D6 Q46589487-CCED336E-73B6-4778-BCDC-706F57567BD5 Q46813086-396AC6BF-00FC-4F8C-AFF9-D27DEBF4B106 Q47632792-E2FA6BA5-3BB4-48C5-A360-377C5F498B68 Q47852798-E322087C-AA4C-4737-9C82-39B77380D049 Q50317039-37FB5097-3BE1-475A-8D44-49A8B43947E0

P2860

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

http://www.wikidata.org/entity/Q34285599

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@ast

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@en

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@nl

type

label

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@ast

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@en

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@nl

prefLabel

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@ast

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@en

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@nl

P1433

Q34285599-8A4BCCAD-2460-49CF-8CB2-82FED912CA65

P1476

Q34285599-9F003249-452F-471B-827E-E104F56F5388

P2093

Q34285599-007AF945-4B85-4336-97DE-6D18C1FB61DE

Q34285599-022E8645-8377-4C4F-A4DD-53CFC1BA94C4

Q34285599-04B92307-9D1D-4E4E-A5E4-C85FFA4552AF

Q34285599-09B4B0CF-6AA8-4D02-B8CA-F31EE3B55C69

Q34285599-0A12E78D-780D-4F5C-8D5D-F5FBB8AAC1F3

Q34285599-1AD0DAA6-0F86-43D1-94F4-0834F03A37D3

Q34285599-1CD2CC55-3B92-40F0-B511-93DC839832A7

Q34285599-20EC787B-C755-42FF-9A0C-FBC9FE90EA50

Q34285599-24DAB874-B16E-4170-A187-74C331BDDE46

Q34285599-290D9636-8140-47ED-A42D-7AFEB01960E9

P2860

Q34285599-2F34E260-7332-4EA2-B873-509417E3D97A

Q34285599-85278258-94EC-4976-A533-94B9DA30F09C

Q34285599-970AACD6-99BA-49BE-A1B4-A7AA72B70565

Q34285599-B1396EF6-E1A1-4A95-B673-673537010C36

Q34285599-B1CC8AE6-D128-47CC-B0F1-22FB2DD79B07

Q34285599-CC866495-F60B-46F6-A17C-DB11BF98932C

Q34285599-D7817914-8B97-46AA-B653-0CF0AB01E8C4

P304

Q34285599-D9FB3115-70B7-4546-AACD-32C447F6A0AE

P31

Q34285599-83AC015B-0A56-4054-B00A-DF1BA687CC22

P356

Q34285599-C09589B8-59C4-4A4C-B03C-9F4B7710BC7D

P407

Q34285599-48435D71-3230-43B0-9C80-EC3FF120C5B9

P433

Q34285599-56EEED75-0CF6-47F2-9BA4-BDAB141AB784

P478

Q34285599-9F9925B0-8355-4FFF-9132-2CA34E22E277

P577

Q34285599-64732930-1F7E-4402-9D1B-C9086CCCBD6C

P5875

Q34285599-53D00345-4523-4A9F-8567-8C6080457223

P698

Q34285599-ADB5FDF5-0A47-424B-B64E-12877F27B7DE

P921

Q34285599-308F7C2A-92E8-4C03-AF17-306C70661DFA

Q34285599-BDC6899E-68E1-4F0F-84C4-D6B86F496ECC

P932

Q34285599-99C0F120-665A-4962-8458-BFAF021D597F

P356

P1433

Clinical Infectious Diseases

P1476

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

@en

P2093

Boris Y Kazennyy

http://www.w3.org/2001/XMLSchema#string

Carmen Contreras

http://www.w3.org/2001/XMLSchema#string

Chang-ki Kim

http://www.w3.org/2001/XMLSchema#string

Charlotte Kvasnovsky

http://www.w3.org/2001/XMLSchema#string

Ekaterina Kurbatova

http://www.w3.org/2001/XMLSchema#string

Elena V Kiryanova

http://www.w3.org/2001/XMLSchema#string

Global Preserving Effective TB Treatment Study (PETTS) Investigators

http://www.w3.org/2001/XMLSchema#string

Grigory V Volchenkov

http://www.w3.org/2001/XMLSchema#string

HeeJin Kim

http://www.w3.org/2001/XMLSchema#string

J Peter Cegielski

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Variable-number tandem repeat typing of Mycobacterium tuberculosis isolates with low copy numbers of IS6110 by using mycobacterial interspersed repetitive units.

Variable selection for propensity score models

Increasing transparency in partnerships for health--introducing the Green Light Committee.

Propensity scores: from naive enthusiasm to intuitive understanding.

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.

The central role of the propensity score in observational studies for causal effects

P304

1049-1063

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIU572

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264633958

http://www.w3.org/2001/XMLSchema#string

P698

25057101

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

multiple drug resistance

P932

4184341

http://www.w3.org/2001/XMLSchema#string